[The efficacy of the antiaggregants ticlid and diabeton in correcting chronic intravascular microcoagulation of the blood in diabetic patients].
Hemocoagulation was examined in 477 diabetes mellitus patients. Whatever the disease type, severity, duration and the intensity of microvascular complications, diabetes mellitus was discovered to be marked by the development of chronic intravascular blood microcoagulation associated with primary hyperactivation of the platelet component of hemostasis. The use of the new antiaggregation agents tiklid and diabeton allows an appreciable decrease of the activity of platelet microthrombus formation whereas the administration of the common sugar-reducing antidiabetic therapy favours the maintenance of its high level.